Tamar is an active investor in emerging technology startups, especially in the blockchain and biotech sectors. Its investments so far reveal several key trends shaping these industries. For blockchain, Tamar favors infrastructure platforms like trading venues and data providers, which have raised huge rounds in the hundreds of millions. It also sees opportunities in Web3, DeFi and NFTs. In biotech, Tamar is bullish on next-gen platforms like precision oncology, RNA therapies and obesity treatments. It has backed multiple startups approaching these spaces in novel ways. Overall, Tamar’s deals signal its ability to identify high-potential startups and catalyze their growth through capital and expertise.
Tamar invests heavily in blockchain trading platforms and data providers
Tamar has made multiple large investments in blockchain trading platforms and data providers, including a $200 million round in PolkaRare, $32 million in Integral, and undisclosed amounts in Hashflow and GlobeDX. These platforms exemplify Tamar’s interest in blockchain infrastructure crucial for mainstream adoption. By supporting institutional-grade exchanges and data tools, Tamar is betting on the growth of crypto as an asset class. The size of these rounds also shows the vast capital flooding into crypto from VCs.
Tamar sees opportunities in Web3, DeFi and NFTs
In addition to infrastructure, Tamar is active in Web3, DeFi and NFTs – some of the hottest themes in crypto now. For example, it backed X World Games, an NFT-based metaverse project, Sukhavati, a Web3 decentralized storage network, and NAOS Finance, a DeFi lending protocol. While skeptical of some niche DeFi and NFT apps, Tamar recognizes the tremendous potential in blockchain-based networks, games and financial services. Its investments here reflect a balanced strategy of finding quality teams in spaces with room for massive growth.
Tamar invests in next-gen platforms like RNA therapies and precision oncology
In biotech, Tamar has funded multiple startups taking revolutionary approaches to drug discovery. This includes ElevateBio, a leading cell and gene therapy incubator; Life Edit, focused on CRISPR gene editing; ReNAgade, developing RNA delivery tech; and Boundless Bio, targeting oncogene amplifications. Such platforms could unlock new treatments for cancer, genetic diseases and more. Tamar also backed more focused startups like Carmot, which targets obesity through novel diabetes pathways. Overall, Tamar is able to identify cutting-edge biotech teams, fund their ambitious visions, and support the commercialization of breakthrough technologies.
Tamar’s deals reveal its skill in scouting high-potential startups
Based on its recent investments, Tamar has demonstrated an ability to identify startups poised for success across emerging tech sectors like blockchain and biotech. Though early stage, these startups are clearly leaders in their niches, whether crypto infrastructure, RNA therapies or Web3 apps. By investing capital and expertise into their growth, Tamar helps concretize their visions into real products and users. Its selective dealmaking reveals a rigorous filtering for quality teams and ideas with large, untapped markets. This allows Tamar to fund the next generation of blockchain and biotech breakouts.
In summary, Tamar’s proficiency in startup investing is evidenced by its recent deals in the blockchain and biotech spaces. By targeting crucial infrastructure and advanced platforms, Tamar backs startups addressing core needs in markets with explosive growth potential. Its investments catalyze the development of better crypto trading, revolutionary therapies and more. Tamar’s ability to identify and support elite teams demonstrates its vital role in transforming promising startups into full-fledged category leaders.